Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of oral VENT-03 in healthy volunteers
NL-OMON58966Phase 1Completed
- Sponsor
- Ventus Therapeutics
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lupus erythematosus (SLE) comparing VENT-03 with Placebo (2 arms). Started Nov 2023; status: completed.
02
Drugs
VENT-03
03
Conditions
lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON58966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58966.